Stockscreener 앱 받기
1.46
2.82%
0.04
시장 영업 전:
1.46
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update - PharmiWeb.com
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Weekly Voice
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) - Weekly Voice
Lineage Cell Therapeutics Price Target Maintained With a $3.00/Share by D. Boral Capital - Moomoo
Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital - Moomoo
LCTX Maintained by D. Boral Capital -- Price Target at $3.00 - GuruFocus
Lineage Cell Therapeutics presents 3-year Phase 1-2a OpRegen trial results in geographic atrophy at summit - Traders Union
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 - Investing News Network
3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 - Business Wire
[ARS] Lineage Cell Therapeutics, Inc. SEC Filing - Stock Titan
Lineage Cell Therapeutics (NYSE American: LCTX) sets 2026 vote on directors, auditor and executive pay - Stock Titan
LCTX Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat
Canaccord Genuity initiates coverage of Lineage Cell Therapeutics (LCTX) with buy recommendation - MSN
Lineage (LCTX) Stock Hot Topic (Risk Aversion) 2026-04-20Revenue Growth Stocks - Xã Châu Thành
Niagen Bioscience And 2 Additional Promising Penny Stocks For Your Consideration - simplywall.st
Lineage Announces Formation of Scientific Advisory Board - BioSpace
Lineage Cell Therapeutics (LCTX) Establishes New Scientific Advi - GuruFocus
Lineage Cell Therapeutics forms advisory board, names clinical head By Investing.com - Investing.com Australia
Lineage Cell Therapeutics forms advisory board, names clinical head - Investing.com
Guidance Update: Can Lineage Cell Therapeutics Inc maintain sales growth2026 Market Trends & Reliable Intraday Trade Alerts - baoquankhu1.vn
Tech Rally: Is Lineage Cell Therapeutics Inc still a buy after recent gains2026 Stock Rankings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
If You Invested $1,000 in Lineage Cell The (LCTX) - Stock Titan
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Finansavisen
Will Lineage (LCTX) Stock Recover Soon | Price at $1.49, Down 0.34%Chart Patterns - Newser
Lineage Cell Therapeutics launches COR1 for corneal diseases amid rising FECD prevalence - Traders Union
Q4 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Pharma News: Can Lineage Cell Therapeutics Inc reach resistance levels soon2026 Technical Overview & AI Enhanced Trading Signals - baoquankhu1.vn
Is Lineage (LCTX) Stock Testing Resistance | Price at $1.58, Up 0.64%Investment Community Signals - Newser
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
Lineage Cell Therapeutics (LCTX) price target increased by 20.00% to 5.10 - MSN
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Lineage Cell Therapeutics pushes scalable platforms to address drug discovery complexity - Traders Union
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance UK
Lineage Cell (LCTX) Launches Its Latest Cell Therapy Program - Yahoo Finance
Earnings Miss: What are the future prospects of Lineage Cell Therapeutics Inc2026 Trade Ideas & Long-Term Growth Stock Strategies - baoquankhu1.vn
Lineage Cell Therapeutics launches new CED cell therapy program - Eyes On Eyecare
10 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Volume Recap: Can Lineage Cell Therapeutics Inc maintain sales growthTrade Performance Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Retail Trends: Is now the right time to enter Lineage Cell Therapeutics IncGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Aug Breakouts: Is Lineage Cell Therapeutics Inc stock overvalued or fairly priced2026 Institutional Moves & Safe Entry Momentum Stock Tips - baoquankhu1.vn
LCTX Should I Buy - Intellectia AI
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
0.14%
0.48%
자본화:
|
볼륨(24시간):